RapidPath™ Myeloid NGS
a next-generation sequencing panel that represents a robust genomic profiling solution for the rapid detection of MDS, MPN and AML.
Pathline Advantage
Results – 3 Day Turnaround Time
Industry leading turnaround time for NGS test.
Regional Laboratory
Pathline is a local, CAP accredited and NY state licensed lab providing pathology expertise and superior service based in Ramsey, NJ.
Enabling Better Clinical Decisions
-
45 gene targeted hot-spot panel for myeloid neoplasm is available.
-
Optimized for scant, low DNA input samples.
-
Includes: ABL1, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MPL, MYD88, NF1, NPM1, NRAS, PHF6, PRPF8, PTPN11, RB1, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, STAG2, TET2, TPT53, U2AF1, WT1, ZRSR2
Provider Choice
A) As a standalone test. Specimen types include bone marrow and peripheral blood.
B) As part of our Comprehensive Hematopathology Analysis and Report. Based on Disease State, tests may include FISH, Cytogenetics, PCR, NGS, Bone Marrow, Morphology, and/or FDA approved 10-Color Flow Cytometry.
